(68)Ga-DOTA-peptides are increasingly used for the detection of neuroendocrine tumors (NET) in clinical trials in Europe. They have been proved accurate for the detection of NET lesions (at primary and metastatic sites) and no adverse effects were recorded. Moreover, providing data on somatostatin receptors expression on NET cells, (68)Ga-DOTA-peptides PET/CT is becoming a fundamental procedure to be performed before starting therapy and to guide treatment with either hot or cold somatostatin analogues. The easy and economic synthesis process is another advantage that is supporting its clinical use even in centers without an on-site cyclotron
Diagnostics and therapy in neuroendocrine tumors (NETs) has been heavily influenced by nuclear medic...
Somatostatin receptor PET tracers such as [68Ga-DOTA,1-Nal3]-octreotide (68Ga-DOTANOC) and [68Ga-DOT...
Neuroendocrine tumours (NET) diagnosis has represented a major challenge in the past decades. The in...
(68)Ga-DOTA-peptides are increasingly used for the detection of neuroendocrine tumors (NET) in clini...
In the past few years, the introduction of novel PET tracers labelled with (68)Ga has changed the di...
Somatostatin receptor PET-CThemploys positron emitting tracers (68Ga-DOTA-peptides) that specificall...
The trend to inform personalized molecular radiotherapy with molecular imaging diagnostics, a concep...
Neuroendocrine tumors (NETs) are characterized by cellular overexpression of somatostatin receptors ...
Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and therapy of...
International audienceContextThe Ga-68-labelled somatostatin analogues (Ga-68-DOTA-SSAs) is becoming...
Objectives: The aim of the present review was to assess the role of combined 18F-Fluorodeoxyglucose ...
Somatostatin receptor positron emission tomography-computed tomography (PET/CT) with 68Ga-1,4,7,10-t...
International audienceNeuroendocrine tumors (NETs) are associated with variable prognosis, with grad...
Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors that require multidisciplinary dis...
Somatostatin receptors are overexpressed in neuroendocrine tumors, whose endogenous ligands are soma...
Diagnostics and therapy in neuroendocrine tumors (NETs) has been heavily influenced by nuclear medic...
Somatostatin receptor PET tracers such as [68Ga-DOTA,1-Nal3]-octreotide (68Ga-DOTANOC) and [68Ga-DOT...
Neuroendocrine tumours (NET) diagnosis has represented a major challenge in the past decades. The in...
(68)Ga-DOTA-peptides are increasingly used for the detection of neuroendocrine tumors (NET) in clini...
In the past few years, the introduction of novel PET tracers labelled with (68)Ga has changed the di...
Somatostatin receptor PET-CThemploys positron emitting tracers (68Ga-DOTA-peptides) that specificall...
The trend to inform personalized molecular radiotherapy with molecular imaging diagnostics, a concep...
Neuroendocrine tumors (NETs) are characterized by cellular overexpression of somatostatin receptors ...
Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and therapy of...
International audienceContextThe Ga-68-labelled somatostatin analogues (Ga-68-DOTA-SSAs) is becoming...
Objectives: The aim of the present review was to assess the role of combined 18F-Fluorodeoxyglucose ...
Somatostatin receptor positron emission tomography-computed tomography (PET/CT) with 68Ga-1,4,7,10-t...
International audienceNeuroendocrine tumors (NETs) are associated with variable prognosis, with grad...
Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors that require multidisciplinary dis...
Somatostatin receptors are overexpressed in neuroendocrine tumors, whose endogenous ligands are soma...
Diagnostics and therapy in neuroendocrine tumors (NETs) has been heavily influenced by nuclear medic...
Somatostatin receptor PET tracers such as [68Ga-DOTA,1-Nal3]-octreotide (68Ga-DOTANOC) and [68Ga-DOT...
Neuroendocrine tumours (NET) diagnosis has represented a major challenge in the past decades. The in...